Axovant Sciences

Renamed Axovant could see big gains in 2019: analysts
Renamed Axovant could see big gains in 2019: analysts
Fierce Biotech
Axovant Sciences
Axovant Gene Therapies
small molecule drugs
Flag link:
Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal
Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal
Endpoints
Axovant Sciences
AXO-Lenti-PD
gene therapy
RNAi
Benitec
Flag link:
Top research execs from Teva, Allergan recruited to help lead Axovant out of the R&D wasteland
Top research execs from Teva, Allergan recruited to help lead Axovant out of the R&D wasteland
Endpoints
Axovant Sciences
R&D
Allergan
Teva Pharmaceutical
Flag link:
The Winners And Losers Of JP Morgan Monday
The Winners And Losers Of JP Morgan Monday
Forbes
JPMHC 2018
Cellular Biomedicine
Alder Biopharmaceuticals
Nevro
Insulet
PTC Therapeutics
Axovant Sciences
Momenta
Natus Medical
Oxford Immunotec
EXACT Sciences
Flag link:
A new Alzheimer’s drug, once worth billions, is headed for the trash
A new Alzheimer’s drug, once worth billions, is headed for the trash
Stat
Alzheimer's disease
Axovant Sciences
intepirdine
dementia with Lewy bodies
Flag link:
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Stat
biotech
Axovant Sciences
intepirdine
SAGE Therapeutics
brexanolone
AbbVie
risankizumab
Global Blood Therapeutics
GBT-440
DBV Technologies
Viaskin Peanut
Cytokinetics
Amicus Therapeutics
ATB200
Spark Therapeutics
Bluebird Bio
Revance Therapeutics
RT002
Flag link:
After Intepirdine Flunked in Alzheimer’s Disease, Is Axovant Sciences a Buy?
After Intepirdine Flunked in Alzheimer’s Disease, Is Axovant Sciences a Buy?
Motley Fool
Axovant Sciences
Alzheimer's disease
intepirdine
Flag link:
Axovant's closely watched Alzheimer's drug fails late-stage trial
Axovant's closely watched Alzheimer's drug fails late-stage trial
BioPharma Dive
Axovant Sciences
Alzheimer's disease
clinical trials
intepirdine
Flag link:
Duchenne muscular dystrophy
Duchenne muscular dystrophy
Motley Fool
Duchenne Muscular Dystrophy
PTC Therapeutics
Translarna
Axovant Sciences
Alzheimer's disease
NASH
Gilead Sciences
Flag link:
Is This the Next Home-Run Biotech Stock?
Is This the Next Home-Run Biotech Stock?
Motley Fool
biotech
Axovant Sciences
intepirdine
RVT-101
Flag link:
A company developing a drug to treat Alzheimer's disease just got a new CEO — and the stock is jumping
A company developing a drug to treat Alzheimer's disease just got a new CEO — and the stock is jumping
Yahoo/Business Insider
Alzheimer's disease
David Hung
Pharma CEOs
Axovant Sciences
Flag link:
Axovant Sinks on Pfizer Alzheimer's Drug Blowup
Axovant Sinks on Pfizer Alzheimer's Drug Blowup
TheStreet.com
Axovant Sciences
Pfizer
Alzheimer's disease
PF-05212377
Flag link:
5 Biotech Predictions for 2016
5 Biotech Predictions for 2016
Motley Fool
biotech
GW Pharma
Medical Marijuana
Big Pharma
Alzheimer's disease
CAR-T
Portola Pharmaceuticals
Eli Lilly
Biogen
Axovant Sciences
Flag link:
Company Run By 30-Year-Old Former Hedge Fund Manager Starts Study To Get Its Alzheimer's Drug Approved
Company Run By 30-Year-Old Former Hedge Fund Manager Starts Study To Get Its Alzheimer's Drug Approved
Forbes
Axovant Sciences
Alzheimer's disease
RVT-101
Flag link:
3 Long Shots Biotech Companies Are Working On
3 Long Shots Biotech Companies Are Working On
Motley Fool
biotech
Alzheimer's disease
Parkinson's Disease
Axovant Sciences
RVT 101
GSK
Biogen
aducanumab
Prothena
PRX-002
Flag link:
What You May Have Missed in Biotech: Cholesterol Drug Scrutiny and a Hedge Fund Alzheimer's Play
What You May Have Missed in Biotech: Cholesterol Drug Scrutiny and a Hedge Fund Alzheimer's Play
Forbes
biotech
GSK
Axovant Sciences
Alzheimer's disease
PCSK9 inhibitors
Praluent
Sanofi
Regeneron
Repatha
Amgen
Flag link:
The 29 Year Old Behind The Giant Biotech IPO That Rose By 90% Speaks
The 29 Year Old Behind The Giant Biotech IPO That Rose By 90% Speaks
Forbes
biotech
IPOs
Axovant Sciences
Flag link: